1 Introduction to Research & Analysis Reports
    1.1 Sickle-cell Anemia Therapeutics Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Sickle-cell Anemia Therapeutics Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Sickle-cell Anemia Therapeutics Overall Market Size
    2.1 Global Sickle-cell Anemia Therapeutics Market Size: 2021 VS 2027
    2.2 Global Sickle-cell Anemia Therapeutics Market Size, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Sickle-cell Anemia Therapeutics Players in Global Market
    3.2 Top Global Sickle-cell Anemia Therapeutics Companies Ranked by Revenue
    3.3 Global Sickle-cell Anemia Therapeutics Revenue by Companies
    3.4 Top 3 and Top 5 Sickle-cell Anemia Therapeutics Companies in Global Market, by Revenue in 2020
    3.5 Global Companies Sickle-cell Anemia Therapeutics Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Sickle-cell Anemia Therapeutics Players in Global Market
        3.6.1 List of Global Tier 1 Sickle-cell Anemia Therapeutics Companies
        3.6.2 List of Global Tier 2 and Tier 3 Sickle-cell Anemia Therapeutics Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Sickle-cell Anemia Therapeutics Market Size Markets, 2021 & 2027
        4.1.2 Blood Transfusion
        4.1.3 Pharmacotherapy
        4.1.4 Bone Marrow Transplant
    4.2 By Type - Global Sickle-cell Anemia Therapeutics Revenue & Forecasts
        4.2.1 By Type - Global Sickle-cell Anemia Therapeutics Revenue, 2016-2021
        4.2.2 By Type - Global Sickle-cell Anemia Therapeutics Revenue, 2022-2027
        4.2.3 By Type - Global Sickle-cell Anemia Therapeutics Revenue Market Share, 2016-2027
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Sickle-cell Anemia Therapeutics Market Size, 2021 & 2027
        5.1.2 Child
        5.1.3 Adult
    5.2 By Application - Global Sickle-cell Anemia Therapeutics Revenue & Forecasts
        5.2.1 By Application - Global Sickle-cell Anemia Therapeutics Revenue, 2016-2021
        5.2.2 By Application - Global Sickle-cell Anemia Therapeutics Revenue, 2022-2027
        5.2.3 By Application - Global Sickle-cell Anemia Therapeutics Revenue Market Share, 2016-2027
6 Sights by Region
    6.1 By Region - Global Sickle-cell Anemia Therapeutics Market Size, 2021 & 2027
    6.2 By Region - Global Sickle-cell Anemia Therapeutics Revenue & Forecasts
        6.2.1 By Region - Global Sickle-cell Anemia Therapeutics Revenue, 2016-2021
        6.2.2 By Region - Global Sickle-cell Anemia Therapeutics Revenue, 2022-2027
        6.2.3 By Region - Global Sickle-cell Anemia Therapeutics Revenue Market Share, 2016-2027
    6.3 North America
        6.3.1 By Country - North America Sickle-cell Anemia Therapeutics Revenue, 2016-2027
        6.3.2 US Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.3.3 Canada Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.3.4 Mexico Sickle-cell Anemia Therapeutics Market Size, 2016-2027
    6.4 Europe
        6.4.1 By Country - Europe Sickle-cell Anemia Therapeutics Revenue, 2016-2027
        6.4.2 Germany Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.3 France Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.4 U.K. Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.5 Italy Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.6 Russia Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.7 Nordic Countries Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.4.8 Benelux Sickle-cell Anemia Therapeutics Market Size, 2016-2027
    6.5 Asia
        6.5.1 By Region - Asia Sickle-cell Anemia Therapeutics Revenue, 2016-2027
        6.5.2 China Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.5.3 Japan Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.5.4 South Korea Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.5.5 Southeast Asia Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.5.6 India Sickle-cell Anemia Therapeutics Market Size, 2016-2027
    6.6 South America
        6.6.1 By Country - South America Sickle-cell Anemia Therapeutics Revenue, 2016-2027
        6.6.2 Brazil Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.6.3 Argentina Sickle-cell Anemia Therapeutics Market Size, 2016-2027
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Sickle-cell Anemia Therapeutics Revenue, 2016-2027
        6.7.2 Turkey Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.7.3 Israel Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.7.4 Saudi Arabia Sickle-cell Anemia Therapeutics Market Size, 2016-2027
        6.7.5 UAE Sickle-cell Anemia Therapeutics Market Size, 2016-2027
7 Players Profiles
    7.1 Addmedica
        7.1.1 Addmedica Corporate Summary
        7.1.2 Addmedica Business Overview
        7.1.3 Addmedica Sickle-cell Anemia Therapeutics Major Product Offerings
        7.1.4 Addmedica Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.1.5 Addmedica Key News
    7.2 Gamida Cell
        7.2.1 Gamida Cell Corporate Summary
        7.2.2 Gamida Cell Business Overview
        7.2.3 Gamida Cell Sickle-cell Anemia Therapeutics Major Product Offerings
        7.2.4 Gamida Cell Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.2.5 Gamida Cell Key News
    7.3 GlycoMimetics
        7.3.1 GlycoMimetics Corporate Summary
        7.3.2 GlycoMimetics Business Overview
        7.3.3 GlycoMimetics Sickle-cell Anemia Therapeutics Major Product Offerings
        7.3.4 GlycoMimetics Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.3.5 GlycoMimetics Key News
    7.4 Pfizer
        7.4.1 Pfizer Corporate Summary
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer Sickle-cell Anemia Therapeutics Major Product Offerings
        7.4.4 Pfizer Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.4.5 Pfizer Key News
    7.5 Novartis
        7.5.1 Novartis Corporate Summary
        7.5.2 Novartis Business Overview
        7.5.3 Novartis Sickle-cell Anemia Therapeutics Major Product Offerings
        7.5.4 Novartis Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.5.5 Novartis Key News
    7.6 Global Blood Therapeutics
        7.6.1 Global Blood Therapeutics Corporate Summary
        7.6.2 Global Blood Therapeutics Business Overview
        7.6.3 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Major Product Offerings
        7.6.4 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.6.5 Global Blood Therapeutics Key News
    7.7 Micelle BioPharma
        7.7.1 Micelle BioPharma Corporate Summary
        7.7.2 Micelle BioPharma Business Overview
        7.7.3 Micelle BioPharma Sickle-cell Anemia Therapeutics Major Product Offerings
        7.4.4 Micelle BioPharma Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.7.5 Micelle BioPharma Key News
    7.8 Bluebird Bio
        7.8.1 Bluebird Bio Corporate Summary
        7.8.2 Bluebird Bio Business Overview
        7.8.3 Bluebird Bio Sickle-cell Anemia Therapeutics Major Product Offerings
        7.8.4 Bluebird Bio Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.8.5 Bluebird Bio Key News
    7.9 Prolong Pharmaceuticals
        7.9.1 Prolong Pharmaceuticals Corporate Summary
        7.9.2 Prolong Pharmaceuticals Business Overview
        7.9.3 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Major Product Offerings
        7.9.4 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.9.5 Prolong Pharmaceuticals Key News
    7.10 Modus Therapeutics
        7.10.1 Modus Therapeutics Corporate Summary
        7.10.2 Modus Therapeutics Business Overview
        7.10.3 Modus Therapeutics Sickle-cell Anemia Therapeutics Major Product Offerings
        7.10.4 Modus Therapeutics Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.10.5 Modus Therapeutics Key News
    7.11 Sangamo Biosciences
        7.11.1 Sangamo Biosciences Corporate Summary
        7.11.2 Sangamo Biosciences Business Overview
        7.11.3 Sangamo Biosciences Sickle-cell Anemia Therapeutics Major Product Offerings
        7.11.4 Sangamo Biosciences Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.11.5 Sangamo Biosciences Key News
    7.12 Bioverativ
        7.12.1 Bioverativ Corporate Summary
        7.12.2 Bioverativ Business Overview
        7.12.3 Bioverativ Sickle-cell Anemia Therapeutics Major Product Offerings
        7.12.4 Bioverativ Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.12.5 Bioverativ Key News
    7.13 Imara
        7.13.1 Imara Corporate Summary
        7.13.2 Imara Business Overview
        7.13.3 Imara Sickle-cell Anemia Therapeutics Major Product Offerings
        7.13.4 Imara Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.13.5 Imara Key News
    7.14 Ironwood Pharmaceuticals
        7.14.1 Ironwood Pharmaceuticals Corporate Summary
        7.14.2 Ironwood Pharmaceuticals Business Overview
        7.14.3 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Major Product Offerings
        7.14.4 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue in Global (2016-2021)
        7.14.5 Ironwood Pharmaceuticals Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer